Surena F Matin, Mehrad Adibi, Amishi Y Shah, Omar Alhalabi, Paul Corn, Charles Guo, Rhenita Amirtharaj, Lianchun Xiao, Suzanne Lange, Dzifa Y Duose, Shufang Wang, Sumanta Pal, Matthew T Campbell
BACKGROUND: We initiated a biomarker-informed preoperative study of infigratinib, a Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients with localized upper tract urothelial carcinoma (UTUC), a population with high unmet needs and tumor with a high frequency of FGFR3 alterations. METHODS: Patients with localized UTUC undergoing ureteroscopy (URS) or nephroureterectomy/ureterectomy (NU/U), were enrolled on a phase 1b trial (NCT04228042). Once-daily infigratinib 125 mg PO × 21 days (28-day cycle) was given for 2 cycles...
April 4, 2024: Journal of Urology